NCT02096861View on ClinicalTrials.gov

Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

September 19, 2014

Primary Completion Date

January 11, 2016

Study Completion Date

February 15, 2017

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

CT-P13

CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose

BIOLOGICAL

Remicade

Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose

Trial Locations (1)

37205

Nashville Medical Research Institute, Nashville

Sponsors

Lead Sponsor

Celltrion

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Celltrion

INDUSTRY

NCT02096861 - Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease | Biotech Hunter | Biotech Hunter